Main Article Content
Nebivolol might be Beneficial in Osteoporosis Treatment: A Hypothesis
Abstract
Nebivolol is a β-blocker that is highly selective for β1-adrenergic receptors with vasodilating properties. This property can be attributed to an endothelial release of nitric oxide (NO). It has been reported that nebivolol also reduces intracellular oxidative stress. There are some studies conducted in humans and animal models which have shown that NO is an important regulator of bone metabolism. However, oxidative stress and antioxidant systems may play important roles in the pathogenesis of osteoporosis. In this paper, we hypothesized that nebivolol may have beneficial effects via nitric oxide and antioxidant action in osteoporosis treatment.